Christine Gilmore, NP
Psychiatric/Mental Health · Bedford, VANPI 1851686356
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,640 of the $74,950 with a category attached, or 64.9%. Neurocrine Biosciences, Inc. accounts for 85.1% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $34,461, more than ten times the $48 reported in 2021. Among psychiatric/mental health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $283.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$64K
- Teva Pharmaceuticals USA, Inc.$8K
- Johnson & Johnson$668
- Alkermes, Inc.$544
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$477
- Otsuka America Pharmaceutical, Inc.$475
- plus $866 from 5 others
What the payments were for
- Consulting fees$17,39323%
- Speaking & faculty fees$48,64065%
- Travel & lodging$3,0034%
- Food & beverage$5,7478%
- Education$1670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 114 | $63,803 |
| Teva Pharmaceuticals USA, Inc. | 29 | $8,118 |
| Johnson & Johnson | 22 | $668 |
| Alkermes, Inc. | 19 | $544 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $477 |
| Otsuka America Pharmaceutical, Inc. | 23 | $475 |
| Lundbeck LLC | 12 | $219 |
| E.r. Squibb & Sons, L.L.C. | 5 | $201 |
| AbbVie | 9 | $178 |
| Axsome Therapeutics, Inc. | 2 | $143 |
| Novo Nordisk | 1 | $124 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$74,950 in reported general payments places this provider in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 68 | $577,096 |
| Austedo XrDeutetrabenazine | 31 | $339,608 |
| Invega TrinzaPaliperidone Palmitate | 29 | $285,930 |
| Invega SustennaPaliperidone Palmitate | 29 | $96,408 |
| LybalviOlanzapine/Samidorphan Malate | 43 | $67,433 |
| RexultiBrexpiprazole | 37 | $55,876 |
| CaplytaLumateperone Tosylate | 23 | $37,669 |
| VraylarCariprazine Hcl | 18 | $26,773 |
| VivitrolNaltrexone Microspheres | 16 | $26,751 |
| Aripiprazole | 161 | $18,439 |
| Paliperidone ErPaliperidone | 27 | $9,726 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $8,714 |
| Olanzapine | 102 | $7,084 |
| BelsomraSuvorexant | 12 | $5,993 |
| Clozapine | 83 | $4,614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $63,803 | $577,09668 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $668 | $382,33858 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Loxapine | $8,118 | $340,91057 claims |
| Alkermes, Inc.Lybalvi, Vivitrol | $544 | $94,18559 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $475 | $55,87637 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $477 | $37,66923 claims |
| AbbVieVraylar | $178 | $26,77318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Other psychiatric/mental health in Bedford
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
- Sarah FaberNewport News$59K
- Kristine GarciaGlen Allen$46K
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
- Juliana FroschAmherst$36K
- Derick ReedyNickelsville$23K
- Pamela RuppelRoanoke$21K
- Lisa Clement DefalcoEarlysville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.